Sun-Novo(SH:688621) Xin Lang Cai Jing·2025-11-07 06:29Core Points - The stock price of Sunshine Nuohe has decreased by 2.00% to 55.36 CNY per share as of November 7, with a total market capitalization of 6.2 billion CNY [1] - The company has experienced a year-to-date stock price increase of 47.47%, but has seen declines of 5.77% over the last five trading days, 9.53% over the last twenty days, and 11.25% over the last sixty days [1] - Sunshine Nuohe's main business involves the development of generic drugs, consistency evaluation, and innovative drug development, with 99.91% of its revenue coming from CRO services [1] Financial Performance - For the period from January to September 2025, Sunshine Nuohe reported a revenue of 856 million CNY, a year-on-year decrease of 6.65%, and a net profit attributable to shareholders of 163 million CNY, down 21.38% year-on-year [2] - The company has distributed a total of 105 million CNY in dividends since its A-share listing, with 84.29 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders has increased by 6.76% to 9,204, while the average number of tradable shares per person has decreased by 6.33% to 12,168 shares [2] - The top ten circulating shareholders include notable entities such as Rongtong Health Industry Flexible Allocation Mixed A/B and Hong Kong Central Clearing Limited, with changes in their holdings noted [3]